65,437 trials
Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients
Type 1 Diabetes
Primary: Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone — 159.7; 144.6 mg/dl
Post Traumatic Stress Disorder · Suicidal Ideation · Nightmares
Primary: Change Score for Scale for Suicide Ideation — 7.6; 8.2 units on a scale
Non-small Cell Lung Cancer · Carcinoma · NSCLC
Primary: Number of Subjects With Treatment-emergent Adverse Events — 2; 1; 1; 0 participants
Central Retinal Vein Occlusion
Primary: Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 — 18.9; 18.6 letters read
Open Wound Abdominal Wall · Wound Non Healing
Primary: Closure Rate of Non-healing Wounds — 45.79; 89.98 percentage of healing
Scar
Primary: POSAS (The Patient and Observer Scar Assessment Scale) Measure — 2.5; 2.5; 2.5 Score
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
Tooth Movement · Malocclusion
Primary: Ability to Complete Treatment Aligners in Conjunction With an Active and Placebo Vibration Device (AcceleDent® Aura) — 10; 11 Participants
Hot Flashes
Primary: Percent Change in Objective Sleep Efficiency — -2.6; 4.2 percent change
Postoperative Complications
Primary: Number of Participants With Postoperative Morbidity (Major Complications) — 103; 91 Participants — p=0.51
Brain and Central Nervous System Tumors
Primary: Proportion of Participants With Objective Response Rate (ORR) — 5 Participants
Head and Neck Cancer · Patients Requiring a Free Flap Surgery
Primary: ICU Stay — 33.7; 58.3 hours
Depressive Disorder · Depression · Depressive Disorder, Major
Primary: Change in the Montgomery-Asberg Depression — -10.4; -8.07 Units on a scale — p=0.0074
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12) — 96.2 percentage of participants